Sound Pharmaceuticals Receives FDA Breakthrough Therapy Designation for SPI-1005 to Treat Meniere’s Disease

Sound Pharmaceuticals’ experimental drug SPI-1005 has received FDA Breakthrough Therapy Designation for treating hearing loss in Meniere’s disease. The oral anti-inflammatory is the first to earn this designation for sensorineural hearing loss, and SPI will work with the FDA toward future approval.